Waldenstrom’s Macroglobulinemia
- 18 September 2016
- book chapter
- other
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalitiesLaboratory Investigation, 2012
- Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activityBlood, 2011
- Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregationBlood, 2010
- Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaBlood, 2009
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemiaBlood, 2007
- Genomewide Linkage Screen for Waldenström Macroglobulinemia Susceptibility Loci in High-Risk FamiliesAmerican Journal of Human Genetics, 2006
- Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myelomaBlood, 2006
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003